A carregar...
H19-Promoter-Targeted Therapy Combined with Gemcitabine in the Treatment of Pancreatic Cancer
Pancreatic cancer is the eighth cancer leading cause of cancer-related death in the world and has a 5-year survival rate of 1–4% only. Gemcitabine is a first line agent for advanced pancreatic therapy; however, its efficacy is limited by its poor intracellular metabolism and chemoresistance. Studies...
Na minha lista:
| Main Authors: | , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
International Scholarly Research Network
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3371723/ https://ncbi.nlm.nih.gov/pubmed/22701803 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5402/2012/351750 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|